Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

December 18, 2020

Study Completion Date

December 18, 2020

Conditions
Ovarian Cancer
Interventions
DRUG

chiauranib

in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily

DRUG

etoposide

50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most

DRUG

paclitaxel

60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY